NMD Pharma

NMD Pharma

Denmark - Aarhus
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Small Molecule Drug Discovery

NMD Pharma is a life sciences company focused on Small Molecule Drug Discovery.

NeurologyRare Diseases
Funding Stage
SERIES A
Employees
51-200
Total Funding
$47M
Open Jobs
0

Products & Portfolio (1)

DI-ATRO
atropine sulfate; diphenoxylate hydrochloride
Post-LOE
ORAL · TABLET
muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis. Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.
older for: Atropine is an anticholinergic agent indicated in adultsolder for: Cycloplegia () Mydriasis () Penalization of the healthy eye in the treatment of amblyopia () 1
1977
30

Pipeline & Clinical Trials

Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
Charcot-Marie-Tooth Disease
N/A
Clinical Trials (1)
NCT04980807Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
N/A
Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
Sarcopenia
N/A
Clinical Trials (1)
NCT04904926Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
N/A
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Muscular Dystrophy, Duchenne
N/A
Phase 2
Clinical Trials (1)
NCT06414954Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Phase 2
Phase 2
Clinical Trials (1)
NCT06482437Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Phase 2
Phase 2
Clinical Trials (1)
NCT05794139Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
Phase 2
Pyridostigmine
Myasthenia Gravis
Phase 3
Clinical Trials (1)
NCT05919407Pyridostigmine and Amifampridine for Myasthenia Gravis
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 6 clinical trials
Top TAs: Neurology, Rare Diseases
Publications: 6 in PubMed
Portfolio Health
Post-LOE1 (100%)
1 total products
Therapeutic Area Focus
Neurology
2 pipeline
Rare Diseases
1 pipeline
Marketed
Pipeline